We are live on
!
Find out more
RA
Rosalind Advisors Portfolio holdings
AUM
$249M
1-Year Est. Return
80.12%
This Fund
S&P 500
This Quarter
Est. Return
-3.3%
1 Year Est. Return
+80.12%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$130M
AUM Growth
+$22.9M
(+21%)
Cap. Flow
+$39.4M
Cap. Flow
% of AUM
30.35%
Top 10 Holdings %
Top 10 Hldgs %
59.82%
Holding
41
New
8
Increased
13
Reduced
5
Closed
2
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Delcath Systems
DCTH
|
+$10.2M |
| 2 |
Abeona Therapeutics
ABEO
|
+$8.93M |
| 3 |
Cellectar Biosciences
CLRB
|
+$6.67M |
| 4 |
Ocular Therapeutix
OCUL
|
+$4.63M |
| 5 |
InspireMD
NSPR
|
+$4.28M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Veru
VERU
|
+$2.09M |
| 2 |
TVRD
Tvardi Therapeutics
TVRD
|
+$1.41M |
| 3 |
Unicycive Therapeutics
UNCY
|
+$303K |
| 4 |
LYRA
LYRA THERAPEUTICS INC
LYRA
|
+$248K |
| 5 |
Kiora Pharmaceuticals
KPRX
|
+$5 |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 97.31% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Fortress Biotech
FBIO
$109M
| $1.04M | 0.8% |
607,797
| – | – |
|
27
Geron
GERN
$860M
| $848K | 0.65% |
200,000
| – | – |
|
28
PUT
Annovis Bio
ANVS
$75.3M
| $839K | 0.65% |
+24,154
| New | +$196K |
|
|
29
Unicycive Therapeutics
UNCY
$145M
| $787K | 0.61% |
157,120
-30,845
| -16% | -$303K |
|
|
SPRB
30
Spruce Biosciences
SPRB
$119M
| $781K | 0.6% |
20,112
| – | – |
|
31
Talphera
TLPH
$70.1M
| $675K | 0.52% |
758,966
| – | – |
|
32
Journey Medical
DERM
$178M
| $644K | 0.5% |
+114,132
| New | +$470K |
|
33
Beyond Air
XAIR
$3.91M
| $486K | 0.37% |
2,259
| – | – |
|
34
Biofrontera
BFRI
$15.7M
| $453K | 0.35% |
504,261
| – | – |
|
|
GTHX
35
PUT
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
| $305K | 0.23% |
+19,018
| New | +$72.6K |
|
|
LYRA
36
DELISTED
LYRA THERAPEUTICS INC
LYRA
| $286K | 0.22% |
20,695
-2,195
| -10% | -$248K |
|
37
NewAmsterdam Pharma
NAMS
$3.33B
| $194K | 0.15% |
+10,123
| New | +$203K |
|
38
BioXcel Therapeutics
BTAI
$24.5M
| $50.8K | 0.04% |
+2,480
| New | +$83K |
|
39
Tonix Pharmaceuticals
TNXP
$161M
| $19.6K | 0.02% |
282
| – | – |
|
40
PUT
Invesco QQQ Trust
QQQ
$450B
| – | – |
-100,000
| Closed | -$7K |
|
|
TVRD
41
Tvardi Therapeutics
TVRD
$19.7M
| – | – |
-43,025
| Closed | -$1.41M |
|
Similar funds
TAM
SCM
FDDB
MC
SCM
GWS
SCM
ER
Rosalind Advisors's Q2 2024 Portfolio in Review
As of Q2 2024, Rosalind Advisors held 41 positions worth $130M, up 21% from $107M the previous quarter. Its ten largest holdings account for 60% of the portfolio.
Rosalind Advisors deployed $39.4M of net new capital in Q2 2024, opening 8 new positions and adding to 13 existing holdings. Its largest new stake was Abeona Therapeutics: 1,750,000 shares worth $7.42M.
By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 100% a quarter earlier.
On the sell side, the largest reduction was Veru, an estimated $2.09M trimmed.
- Rosalind Advisors's largest Q2 2024 buy was Abeona Therapeutics: 1,750,000 shares worth $7.42M.
- Rosalind Advisors added most to Delcath Systems in Q2 2024, an estimated $10.2M increase.
- Rosalind Advisors's biggest Q2 2024 reduction was Veru, cutting an estimated $2.09M.
- Rosalind Advisors fully exited Tvardi Therapeutics in Q2 2024, selling an estimated $1.41M.
- Rosalind Advisors's ten largest holdings make up 60% of its $130M portfolio in Q2 2024.
- Rosalind Advisors opened 8 new positions and closed 2 in Q2 2024.
- Rosalind Advisors's portfolio value rose 21% quarter-over-quarter to $130M.
Based on Rosalind Advisors's 13F filing for Q2 2024, filed 12 Jul 2024.